Day: March 14, 2022

Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022 New program VCAR33ALLOusing healthy donor-derived T cells IND submission expected in 1H 2023Cash runway extended into Q4 2023 providing additional financial flexibility and optionalityCAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2021, and provided a business update.  “2022 is a pivotal year for Vor Bio with a number of catalysts that will continue to validate the potential of our platform,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “We are focused on recruitment and enrollment of patients in VBP101, the Phase 1/2a trial of VOR33, our lead...

Revenues Grow 53%; New VP Global Sales & Marketing Appointed MONROE TOWNSHIP, N.J., March 14, 2022 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine data, power, and consulting service solutions, today announced financial results for its third quarter ended January 31, 2022. BUSINESS HIGHLIGHTSAs previously announced, the Company completed its acquisition of Marine Advanced Robotics (MAR) on November 15, 2021, expanding OPT’s commercial offering into autonomous vehicles for maritime data services. MAR is expected to contribute approximately $2.0 million to revenue for Fiscal Year 2023. In the 3Q22, the Company recognized $257,000 of revenue related to MAR. Revenues grew 53% to $484,000...

Full Year 2021US$6.0 billion Total Payment Volume, up 193% year-over-yearRevenues of US$244.1 million, up 134% year-over-year219% Net Retention Rate41% Adj EBITDA Margin Fourth Quarter 2021 US$1.9 billion Total Payment Volume, up 145% year-over-year Revenues of US$76.3 million, up 120% year-over-year 198% Net Retention Rate38% Adj EBITDA Margin dLocal reports in US dollars and in accordance with IFRS as issued by the IASB MONTEVIDEO, Uruguay, March 14, 2022 (GLOBE NEWSWIRE) — DLocal Limited (“dLocal”, “we”, “us”, and “our”) (NASDAQ:DLO), a technology-first payments platform today announced its financial results for the fourth quarter and full year ended December 31, 2021. “Dear Customers, Partners and Shareholders, Thank you for your continued support and trust. We started our journey a little over 6 years ago and we are proud...

FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022. Company ended 2021 with $107.9 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced fourth quarter and full year 2021 results and provided a corporate update. “2021 was a milestone year for aTyr, which culminated in clinical proof-of-concept for our lead therapeutic candidate, efzofitimod (ATYR1923), and validation for our tRNA synthetase biology...

Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022 WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2021 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We have completed blinded data collection from the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19 and look forward to unblinding and subsequently reporting results of the study in the last week of this month. We believe rNAPc2 has the potential...

Announced strategic reprioritization, with plans to advance mucopolysaccharidosis type I (MPS-1) and diabetes as lead indications as well as continued platform optimization Strengthened leadership team with appointment of new Chief Technical Operations Officer and other key leadership changes Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and full year ended December 31, 2021 as well as certain other business highlights. “In 2021, we made important adjustments to our overall corporate and clinical strategy as well as our leadership...

Atlanta, March 14, 2022 (GLOBE NEWSWIRE) — Acuity Brands, Inc. (NYSE: AYI) (“Company”) today announced that the Company is planning to release its fiscal 2022 second-quarter earnings results on Tuesday, April 5, at 6:00 a.m. (EDT) to be followed by a conference call at 8:00 a.m. (EDT).  Neil Ashe, Chairman, President and Chief Executive Officer of Acuity Brands, will lead the call.   The conference call and earnings release can be accessed via the Investor Relations section of the Company’s website at investors.acuitybrands.com. The online replay will remain available for a limited time following the call. A replay of the call will also be posted to the Investor Relations site within two hours of the completion of the conference call and will be archived on the site.   To learn more about Acuity Brands, please visit the Company’s website....

Continues to Consolidate Portfolio Through Attractive Buy-Outs of JV Partners GREAT NECK, N.Y., March 14, 2022 (GLOBE NEWSWIRE) — BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust that owns, operates and, to a lesser extent, develops multi-family properties, today reported that for the three months ended December 31, 2021, it generated a net loss of $1.25 million, or $0.08 per diluted share, FFO1 of $6.3 million, or $0.35 per diluted share, and AFFO of $7.5 million, or $0.41 per diluted share, and that for the twelve months ended December 31, 2021, it generated net income of $29.1 million, or $1.62 per diluted share, FFO of $17.43 million, or $0.97 per diluted share, and AFFO of $23.81 million, or $1.33 per diluted share. Jeffrey A. Gould, President and Chief Executive Officer of BRT stated, “Our portfolio continued...